Valsartan Prices

Valsartan Prices September 2024

The valsartan prices in the United States for Q3 2024 reached 84,300 USD/MT in September. The region saw notable price fluctuations. Early price surges were supported by strong consumer sentiment and disrupted supply chains. However, August and September marked a rapid drop in demand, prompting price cuts amid decreasing inflation and eased business overheads due to falling energy prices.

The price trend for valsartan in China for Q3 2024 settled at 83,400 USD/MT in September. The market witnessed a mixed trend. Initial price growth was driven by strong export activity and strategic bulk orders by importers. Yet, as the quarter moved into August-September, demand weakened, influenced by reduced exports and anti-dumping strategies imposed by major international markets.

In Germany, the valsartan prices for Q3 2024 reached 85,450 USD/MT in September. The market experienced both upward and downward price movements. Early in the quarter, consumer optimism and seasonal demand boosted prices. Later, economic challenges, lower inflation, and reduced energy prices led to a decline in domestic demand, prompting suppliers to reduce prices to adapt to the shifting landscape.

Valsartan Prices June 2024

The valsartan prices in the United States for Q2 2024 reached 91,300 USD/MT in June. The region experienced notable price shifts due to strong consumer demand and supply chain disruptions early in the quarter. However, by June, economic concerns and reduced demand led to declining prices, reflecting an improved supply situation and cautious market sentiment.

The price trend for valsartan in China for Q2 2024 settled at 90,150 USD/MT in June. The prices initially rose due to high manufacturing output spurred by strong domestic and international demand. However, an oversupply and reduced raw material and transport costs later drove prices down. Economic challenges in key export markets further weakened demand and kept prices low.

In Germany, the valsartan prices for Q2 2024 reached 92,200 USD/MT in June. The market began with a price increase supported by consumer spending and economic optimism. However, rising operational expenses and slowing demand led to a price drop by June. Furthermore, improved supply chain conditions and reduced freight costs contributed to this downward trend, stabilizing prices.

Valsartan Prices December 2023

The valsartan prices in the United States for Q4 2023 reached 96995 USD/MT (US FDA) in December. The prices in the United States experienced moderate increased in the last quarter of the same year due to strong demand and limited supply. Despite high rate of interests, improved consumer confidence initially supported this upward trend. However, by December, concerns about the economic future and consistent increased interest rates resulting in a decline in consumer assurance and prices of valsartan.

The price trend for valsartan in China for Q4 2023, reached 95995 USD/MT (US FDA) in December. The pricing in China experienced stability despite significant year-over-year declines. The market was influenced by stable supply levels and robust demand, yet external uncertainties and weak domestic requirements presented difficulties. Pricing remained unchanged throughout the quarter, reflecting a cautious and stable market environment.

The price trend for valsartan in Germany for Q4 2023, reached 99595 USD/MT (US FDA) in December. The prices in across the country during this quarter remained stable, supported by a gradual economic recovery and improved manufacturing conditions. A decline in consumer inflation bolstered purchasing power, maintaining price stability. However, December saw a price decline as inflation rebounded, affecting demand and leading suppliers to change prices to sell ample inventory.

Regional Coverage

The report provides a detailed analysis of the valsartan market across different regions, each with unique pricing dynamics influenced by localized market conditions, supply chain intricacies, and geopolitical factors. This includes price trends, price forecast and supply and demand trends for each region, along with spot prices by major ports. The report also provides coverage of ex-works, FOB, and CIF prices, as well as the key factors influencing the valsartan price trend.

Global Valsartan Price

The report offers a holistic view of the global valsartan pricing trends in the form of valsartan price charts, reflecting the worldwide interplay of supply-demand balances, international trade policies, and overarching economic factors that shape the market on a macro level. This comprehensive analysis not only highlights the current price but also provides insights into valsartan historical price trends, enabling stakeholders to understand past fluctuations and their underlying causes.

The report also delves into valsartan price forecast models, projecting future price movements based on a variety of indicators such as expected changes in supply chain dynamics, anticipated policy shifts, and emerging market trends. By examining these factors, the report equips industry participants with the necessary tools to make informed strategic decisions, manage risks, and capitalize on market opportunities. Furthermore, it includes a detailed valsartan demand analysis, breaking down regional variations and identifying key drivers specific to each geographic market, thus offering a nuanced understanding of the global pricing landscape.

Europe Valsartan Price

Q3 2024:

During Q3 2024, the valsartan prices in Europe varied, with Germany being the most impacted. The quarter began with price increases driven by strong consumer activity, seasonal demand peaks, and logistical hurdles, notably in the sea route, which pushed up shipping costs. However, by August and September, economic challenges faltered consumer sentiment and reduced domestic demand. Moreover, lower inflation and energy costs, coupled with beneficial base effects, facilitated ease pricing pressures, prompting suppliers to adjust their pricing downward. This shift highlighted the influence of economic conditions and logistical factors on market strategies.

Q2 2024:

During Q2 2024, the valsartan market in Europe faced a mixed pricing environment driven by diverse factors. Early in the quarter, a positive economic backdrop spurred consumer spending, boosting demand and initially pushing up prices. However, rising operational costs from increased wages and energy expenses added pressure. As June unfolded, slowing consumer demand and an oversupplied market began to weigh on prices. Moreover, falling freight rates, influenced by reduced global supply chain disruptions and stabilizing geopolitical conditions, supported a downward pricing trend. Additionally, central bank policy maintaining interest rates added financial strain on consumers, contributing to weaker purchasing activity toward the end of the quarter.

Q4 2023:

In Q4 2023, the pricing in Europe was impacted by market conditions in Germany, the region's prominent market. Prices remained stable for most of the quarter, reflecting a gradual economic recovery and recovered situations in the manufacturing industry. Germany saw a decrease in consumer inflation, which boosted purchasing capacity and helped stabilize valsartan prices. The market also saw an ample supply, with suppliers adjusting prices to sell excess stock, contributing to the overall price stability.

This analysis can be extended to include detailed valsartan price information for a comprehensive list of countries.

North America Valsartan Price

Q3 2024:

Throughout the third quarter of 2024, valsartan prices in North America displayed an initial rise followed by a sharp decline as the quarter moved forward. July saw an increase fueled by stronger consumer confidence and disrupted supply chains due to shipping reroutes amid port congestion. However, by August and September, a rapid dip in demand led to price cuts as sellers aimed to boost sales. In addition, the reduction in inflation, supported by lower energy costs, provided businesses with an opportunity to ease overheads and adjust consumer prices downward, further influencing the declining trend.

Q2 2024:

Throughout the second quarter of 2024, the valsartan market in North America saw significant price shifts due to various factors impacting the pharmaceutical industry. Initial price surges in both April and May were attributed to robust domestic demand and resilient consumer spending, even amid cost fatigue. Contributing to these increases were disruptions in shipping routes, which led to higher fuel expenses and charter rates as operators adapted with faster transit speeds. However, as June approached, economic uncertainties grew, dampening business sentiment and demand in the pharmaceutical sector. This shift led to a notable price reduction as improved supply conditions emerged, stabilizing the market.

Q4 2023:

In the fourth quarter of 2023, prices in North America were shaped by various factors. Prices rose moderately in initial two months due to increased demand and limited inventory, influenced by improved business activity and easing inflation. However, by December, demand reduced domestically and internationally, causing a decline in prices. The U.S. market experienced the most notable fluctuations, with prices initially climbing due to a supply shortage and heightened consumer confidence. Although interest rates remained high, consumer confidence rebounded after several months of decline, supporting the price increase.

Specific valsartan historical data within the United States and Canada can also be provided.

Middle East and Africa Valsartan Price

The report explores the valsartan pricing trends in the Middle East and Africa, considering factors like regional industrial growth, the availability of natural resources, and geopolitical tensions that uniquely influence market prices.

In addition to region-wise data, information on valsartan prices for countries can also be provided.

Asia Pacific Valsartan Price

Q3 2024:

In Q3 2024, valsartan pricing across the Asia Pacific region was marked by initial price hikes followed by significant declines. Early gains were driven by robust global demand and proactive bulk ordering by foreign importers aiming to mitigate supply risks. This momentum, however, reversed as August and September brought weakened export activity and falling demand. Furthermore, the deployment of anti-dumping initiatives by markets such as India, USA, and Europe, added pressure, dampening the overall regional demand. By the quarter’s end, the market reflected reduced economic momentum and challenges in sustaining price levels.

Q2 2024:

The valsartan market in Asia Pacific during Q2 2024 experienced notable price variations influenced by shifting market dynamics. Early in the quarter, prices rose on the back of increased manufacturing activity and strong domestic and global demand. This prompted a surge in production to meet elevated order volumes. However, later in the quarter, prices began to fall because of an oversupply scenario, where manufacturing output surpassed current demand levels. Seasonal health trends also impacted consumption, reducing the need for Valsartan treatments. Coupled with declining raw material and transportation costs, this set the stage for lower pricing as external demand weakened under economic pressures.

Q4 2023:

During Q4 2023, the pricing in the Asia Pacific region was shaped by a combination of factors. The market remained relatively stable, supported by subdued levels of supply and robust demand from downstream sectors. Despite this, market outlook was cautious, influenced by slow exports and complex geopolitical conditions. In China, the most significant pricing changes were observed, with a notable year-over-year decline. Stability was maintained throughout the quarter, however external uncertainties and weak domestic demand posed ongoing challenges.

This valsartan price analysis can be expanded to include a comprehensive list of countries within the region.

Latin America Valsartan Price

The analysis of valsartan prices in Latin America provides a detailed overview, reflecting the unique market dynamics in the region influenced by economic policies, industrial growth, and trade frameworks.

This comprehensive review can be extended to include specific countries within the region.

Valsartan Price Trend, Market Analysis, and News

IMARC’s newly published report, titled “Valsartan Prices, Trend, Chart, Demand, Market Analysis, News, Historical and Forecast Data Report 2024 Edition,” offers an in-depth analysis of valsartan pricing, covering an analysis of global and regional market trends and the critical factors driving these price movements.

It encompasses an in-depth review of spot price of valsartan at major ports, a breakdown of prices including Ex Works, FOB, and CIF, alongside a region-wise dissection of valsartan price trend across North America, Europe, Asia Pacific, Latin America, the Middle East and Africa.

The report examines the elements influencing valsartan price fluctuations, such as changes in raw material costs, supply-demand dynamics, geopolitical factors, and industry-specific developments. Additionally, it integrates the latest market news, providing stakeholders with up-to-date information on market shifts, regulatory changes, and technological advancements, thereby offering a comprehensive overview that aids in strategic decision-making and forecasting.

Valsartan Market Analysis

The global valsartan market size reached US$ 5.1 Billion in 2023. By 2032, IMARC Group expects the market to reach US$ 7.7 Billion, at a projected CAGR of 4.70% during 2023-2032.

• The increasing number of cardiovascular diseases, such as hypertension and heart failure, is elevating the product’s demand due to its effectiveness in treating the diseases, which is one of the primary factors providing a considerable thrust to the market growth. As per the Centers for Disease Control and Prevention (CDC), in the United States, about 1 person dies every 33 seconds from cardiovascular disease. About 695,000 people in the country have died from heart disease in 2021—that's 1 in every 5 deaths.
• Moreover, the increasing product demand due to growing geriatric population predominantly in developed countries where cardiovascular diseases are more prevalent, is acting as another growth-inducing factor.
• The increased global awareness of early diagnosis and medical treatment of cardiovascular disorders has compelled the patients to select pharmacological treatments such as valsartan, which is creating a positive outlook for the market growth.
• In line with this, the surge in the number of unhealthy lifestyles, such as inactive livelihoods and unhealthy eating, has resulted in a marked and rising occurrence of CVD, thus fueling the market growth.
• Furthermore, technological advancements in drug development are spawning novel formulations and combinations of the product, improving its effectiveness and applicability in clinical practice, which is stimulating the market growth.
• Increased global health spending and greater access to health services in developing countries contribute to the consumption of more affordable and accessible variants of this pharma API.
• Additionally, promoter programs and other government-funded initiatives to promote cardiovascular health and sustainable healthcare are also expanding the market growth.
• The market is further expanding as pharmaceutical companies collaborate to manufacture and distribute other potent and sustainable product formulations and improve their competitive position, which is facilitating the market growth.
• Apart from this, burgeoning investments in research and development (R&D) activities have spurred innovation in the production and development of this drug, which is considerably supporting the market growth.

Valsartan News

The report covers the latest developments, updates, and trends impacting the global valsartan market, providing stakeholders with timely and relevant information. This segment covers a wide array of news items, including the inauguration of new production facilities, advancements in valsartan production technologies, strategic market expansions by key industry players, and significant mergers and acquisitions that impact the valsartan price trend.

Latest developments in the valsartan industry:

• In 2020, Novartis announced new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode.
• In 2020, Pfizer Inc. announced it has completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. to form Viatris Inc.

Product Description

Valsartan is a widely prescribed medication belonging to the class of angiotensin II receptor blockers (ARBs), renowned for its efficacy in managing various cardiovascular conditions, particularly hypertension and heart failure. This pharmaceutical compound exerts its therapeutic effects by selectively blocking the action of angiotensin II on the angiotensin II type 1 (AT1) receptors, leading to vasodilation, reduced aldosterone secretion, and consequent lowering of blood pressure. Marketed under various brand names, this medication is available in oral formulations, including tablets and oral suspensions, catering to diverse patient needs and preferences.

As a cornerstone therapy for hypertension, this pharmaceutical compound plays a pivotal role in the comprehensive management of elevated blood pressure, either as a monotherapy or in combination with other antihypertensive agents. Its ability to effectively control blood pressure levels helps mitigate the risk of cardiovascular events, such as stroke and myocardial infarction, thereby enhancing patient outcomes and quality of life. Moreover, valsartan demonstrates favorable tolerability and safety profiles, making it suitable for long-term use in patients with chronic hypertension.

In addition to its antihypertensive properties, this compound is indicated for the treatment of heart failure, particularly in patients with reduced ejection fraction. By antagonizing the detrimental effects of angiotensin II on cardiac remodeling and neurohormonal activation, it helps alleviate symptoms of heart failure, improve exercise tolerance, and reduce the risk of hospitalization due to heart failure exacerbations. Its inclusion in heart failure management protocols underscores its significance as a cornerstone therapy in optimizing patient outcomes and reducing disease burden.

Report Coverage

Key Benefits for Stakeholders:

• IMARC’s report presents a detailed analysis of valsartan pricing, covering global and regional trends, spot prices at key ports, and a breakdown of Ex Works, FOB, and CIF prices.
• The study examines factors affecting valsartan price trend, including raw material costs, supply-demand shifts, geopolitical impacts, and industry developments, offering insights for informed decision-making.
• The competitive landscape review equips stakeholders with crucial insights into the latest market news, regulatory changes, and technological advancements, ensuring a well-rounded, strategic overview for forecasting and planning.
• IMARC offers various subscription options, including monthly, quarterly, and biannual updates, allowing clients to stay informed with the latest market trends, ongoing developments, and comprehensive market insights. The valsartan price charts ensure our clients remain at the forefront of the industry.